HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-To-OTC “Switchability” Initiation Rights May Require Legislation – Juhl

This article was originally published in The Tan Sheet

Executive Summary

Legislative action may be necessary to clarify who controls the Rx-to-OTC switch potential of a drug, University of Pittsburgh Vice Chancellor for Research Conduct & Compliance Randy Juhl, PhD, asserted
Advertisement

Related Content

Chronic Condition OTC Switches May Take Up To Seven Years – Consultant
Chronic Condition OTC Switches May Take Up To Seven Years – Consultant
Chronic Condition OTC Switches May Take Up To Seven Years – Consultant
Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

Topics

Advertisement
UsernamePublicRestriction

Register

PS094565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel